Cytarabine

Catalog No.S1648

Cytarabine Chemical Structure

Molecular Weight(MW): 243.22

Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

Size Price Stock Quantity  
USD 97 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Viability and CI vs Fa after 24-h exposure to cytarabine alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM (500 ng/ml for cytarabine; quadruplicates±s.e.m.).

    Leukemia, 2015, 29(8): 1702–1712. Cytarabine purchased from Selleck.

    Cell cycle was analyzed using propidium iodide (PI) staining and flow cytometry. The plots show PI staining at the x-axis and cell counts at the y-axis. The graphs were prepared using ModFit LT™ software (Verity Software House). Nd: not detected, Ara-c:Cytarabine

    J Exp Clin Cancer Res, 2017, 36(1):22. Cytarabine purchased from Selleck.

  • Flow cytometry analysis for cell surface expression of CD11b shows time- and dose-dependent upregulation of the marker CD11b in MLL-rearranged leukemia cells treated with EPZ-5676 and Cytarabine(Ara-C) as single agents and in combination.

    J Pharmacol Exp Ther, 2014, 350(3): 646-56. Cytarabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.
Features The 1st of a series of cancer drugs that alters the sugar component of nucleosides.
Targets
DNA synthesis [1]
(CCRF-CEM cells)
16 nM
In vitro

Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. [1] Increasing concentrations of Cytarabine (IC50 of 0.69 μM) results in decreased metabolic activity of sensitive rat leukemic cell line RO/1, and the cell toxity can be highly enhanced by transfection with human wt dCK (IC50 of 0.037 μM) but not the inactive, alternatively spliced dCK forms. [2] Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse L1210 cells NELrdFhEgXSxdH;4bYPDqGG|c3H5 M4fGNlMh\GG7cx?= NGn2O29EgXSxdH;4bYNqfHliYXfhbY5{fCCmZX;4fY52[2ynb4Pp[IUh[W6jbH;neYUue2Wwc3n0bZZmKG2xdYPlJGwyOjFyIHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9NE41KG6PLh?= M3P6dlE6Pjd2OUCz
human CCRF-CEM cells M3L5TmN6fG:2b4jpZ:Kh[XO|YYm= MnXaN{Bl[Xm| NEGxbW1EgXSxdH;4bYNqfHliYXfhbY5{fCCmZX;4fY52[2ynb4Pp[IUh[W6jbH;neYUue2Wwc3n0bZZmKGi3bXHuJGNEWkZvQ1XNJINmdGy|IHHmeIVzKDNiZHH5d{BjgSCPVGSgZZN{[XluIFnDOVA:OSCwTT6= MUSxPVY4PDlyMx?=
human MCF7 cells NWnK[XlpS3m2b4TvfIlkyqCjc4PhfS=> M4LDUFMh\GG7cx?= M3\DTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGSnb4j5cpVkdGWxc3nk[UBidmGub3f1[U1{\W6|aYTpeoUhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUSgcm0v MkTzNVk3PzR7MEO=
CCRF-CEM cell line NWrPZ4pNTnWwY4Tpc44h[XO|YYm= NHzUSnpKdmirYnn0JJRp\SC{ZYDsbYNifGmxbjDv[kBES1KILVPFUUBk\WyuIHzpcoUhcW5idnn0do8tKEWGNUC9OUBvVS5? M3HjOVE6QTV6OUS=
human P12-ICHIKAWA cell M1L3VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYPJcohq[mm2aX;uJI9nKGi3bXHuJHAyOi2LQ1jJT2FYSSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNUSgcm0v MoHEV2FPT0WU
human CCRF-CEM cells Mlz1R5l1d3SxeHnjxsBie3OjeR?= NE\4fms1QCCq M3HC[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNEWkZvQ1XNJINmdGy|IHHmeIVzKDR6IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO|YYmsJGVEPTB;NT62NUBvVS5? MkHiNVk4PDN6NUi=
CCRF-CEM cell lines MkH2SpVv[3Srb36gZZN{[Xl? M1uwTlczKGh? NH7WXo1Ed26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgdoVxdGmlYYTpc44hd2ZiQ1PSSk1ETU1iY3XscEBtcW6nczDifUA2OCViYX\0[ZIhPzJiaIKgbY5kfWKjdHnvckwhTUR3ME22JI5ONg>? NUDiXZIyOTZ3MkCyOC=>
human CCRF-CEM cells NGL1XY9EgXSxdH;4bYPDqGG|c3H5 NVmwe3NvPDhiaB?= NI\HVZJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliY3XscJRqfGW{LXLseYUh[XO|YYmsJGlEPTB;NjDuUU4> MXqyNlU5Ojl7MR?=
human SF268 cells MnviR5l1d3SxeHnjxsBie3OjeR?= NXLrbYFuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUeuOlghdk1w NGHUPGMyQTN2NUW4NS=>
MOLT-4 human leukemic lymphoblastoid cell lines MWDDfZRwfG:6aXRCpIF{e2G7 MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBOV0yWLUSgbJVu[W5ibHX1b4VucWNibIntdIhw[myjc4TvbYQh[2WubDDsbY5meyxiSVO1NF0yOCCwTT6= NVH6dpY3Pjh{N{W0Oi=>
human 697 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEDNZ5FKdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlYhdk1w NYe3[WhPW0GQR1XS
human ES1 cell NFXWRmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M33oUWlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKuPVchdk1w MUXTRW5ITVJ?
CCRF-CEM human leukemic lymphoblastoid cell lines Mm\QR5l1d3SxeHnjxsBie3OjeR?= M2PQT2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEOFUl[tR2VOKGi3bXHuJIxmfWunbXnjJIx6dXCqb3LsZZN1d2mmIHPlcIwhdGmwZYOsJGlEPTB;MkCgcm0v MlHjOlgzPzV2Nh?=
P388 murine cell lines Mn62SpVv[3Srb36gZZN{[Xl? MUS3NkBp NF\VZ|RVcGViY3;tdI92dmRid3HzJJRme3SnZDDpckB3cXS{bzDmc5Ih[W62aYT1cY9zKGGldHn2bZR6MDVyJTDpcohq[mm2aX;uJI9nKHS3bX;yJINmdGxiZ4Lve5RpMSCjZ3HpcpN1KHSqZTDQN|g5KG23cnnu[UBk\WyuIHzpcoV{KGGodHXyJFczKGixdYLzMEBKTDVyPUKwJI5ONg>? MnvhN|YzPTdzNB?=
L1210 murine cell lines M3;KO2Z2dmO2aX;uJIF{e2G7 NGe0SXk4OiCq NVL6TmduXGinIHPvcZBwfW6mIIfhd{B1\XO2ZXSgbY4hfmm2cn:g[o9zKGGwdHn0eY1weiCjY4Tpeol1gSh3MDWgbY5pcWKrdHnvckBw\iC2dX3vdkBk\WyuIHfyc5d1cCliYXfhbY5{fCC2aHWgUFEzOTBibYXybY5mKGOnbHygcIlv\XNiYX\0[ZIhPzJiaH;1dpMtKEmGNUC9NlAhdk1w NGHaclg{PjJ3N{G0
human HEL cell NEDhTpRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV\abWgyUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNE42OiCwTT6= NXnofZNPW0GQR1XS
human CCRF-CEM/C2 cells NULPNm9iS3m2b4TvfIlkyqCjc4PhfS=> NWq0bHlyPDhiaB?= MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDR3JHNUOHTT;DNkBk\WyuczDh[pRmeiB2ODDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBGSzVyPUKyMlghdk1w NVLp[mVCOTl5NEO4OVg>
mouse L1210 cells MXjDfZRwfG:6aXRCpIF{e2G7 Mlq1OFghcA>? NIXudnNEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNOTJzMDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA1QCCqcoOsJGlEPTB;MD6wNlQh|ryPLh?= MV:yNFAxODRzOB?=
human CEM cells MUjDfZRwfG:6aXRCpIF{e2G7 MljjOFghcA>? NW\tWo5FS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0WPIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFQ5KGi{czygTWM2OD1yLkCyOEDPxE1w MXiyNFAxODRzOB?=
human 2209-23 cells M{DhTnBzd2yrZnXyZZRqd25iYYPzZZk> MkPaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiB{MkC5MVI{KGOnbHzzJIJ6KFt|SG30bJlucWSrbnWgbY5kd3Kyb4LheIlwdiC|Y3nueIltdGG2aX;uJJBzd3irbXn0fUBie3OjeTygTWM2OD1yLkCyPUDPxE1? NHvTVosyQTB3NUS4Ni=>
human CHP-212 cell NGLEdG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYTW[YZPUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzNwNEegcm0v MX;TRW5ITVJ?
human CTB-1 cell M1vxVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MULJcohq[mm2aX;uJI9nKGi3bXHuJGNVSi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{SuN{BvVQ>? M3HzenNCVkeHUh?=
human A427 cell NGHlcJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWnJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|ND60PUBvVS5? Mn3aV2FPT0WU
human MOLT-16 cell M37tV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnvPTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|YvODdibl2u NUDB[lNPW0GQR1XS
human MCF7 1K cells MnvER5l1d3SxeHnjxsBie3OjeR?= NVjuVXZOOyCmYYnz MnL0R5l1d3SxeHnjbZR6KGGpYXnud5Qh\GWxeInueYNt\W:|aXTlJIFv[WyxZ4XlMZJme2m|dHHueEBpfW2jbjDNR2Y4KDGNIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJJJq[m:wdXPs[Y91cWSnIILl[JVkfGG|ZTDh[pRmeiB|IHThfZMh[nliTWTUJIF{e2G7LDDJR|UxRTRyIH7NMi=> M17CfVE6Pjd2OUCz
human MC-IXC cell MoHES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIrSSopKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQyNjRzIH7NMi=> MXjTRW5ITVJ?
human BHT-101 cell M2PrXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmPoTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFEvPzZibl2= MlHUV2FPT0WU
human K5 cell NUS3U5hHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXjJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDNwMjDuUS=> MUDTRW5ITVJ?
parent promyelocytic leukemia cell line MUfGeY5kfGmxbjDhd5NigQ>? NF\IdGdCdnSrY3HuZ4VzKGGldHn2bZR6KHejczDleoFtfWG2ZXSg[o9zKHSqZTDjc41xd3WwZDDh[4FqdnO2IIDhdoVvfCCycn;tfYVtd2O7dHnjJIxmfWunbXnhJINmdGxibHnu[UApUExvNkCtS2hRWlRtL3TDT{sqNCCHREWwQVQ4KG6PLh?= NF3IZYc{ODJ5M{K5
human HL60 cells MWTDfZRwfG:6aXRCpIF{e2G7 NUDLWoduS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkh[2WubITpeIVzNWKudXWgZZN{[XluIFnDOVA:OC5yNEmg{txONg>? M4jwRVIzPTh{OUmx
human A549 cell NX\Lb5ZQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX64TJJ5UW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFkvPjZibl2= NVnsN|RuW0GQR1XS
human NCI-H1703 cell M4HxeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M320emlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|A{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDlwOEGgcm0> M2foXHNCVkeHUh?=
L1210 cell lines NIj0emlHfW6ldHnvckBie3OjeR?= MU\Dc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRicnXwcIlk[XSrb36gc4YhVDF{MUCgZ4VtdCCuaX7ld{BjgSB3MDWgZYZ1\XJiN{KgbJIhcW6ldXLheIlwdixiRVS1NF0xNjB3IN88UU4> NHn6co4yPjV{MEK0
human K562 cells MUPDfZRwfG:6aXRCpIF{e2G7 M1vUZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMEWg{txO MViyOFk2PjV3Nh?=
human LB2241-RCC cell NHKxZ2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NG[1S2JKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkK0NU1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13NT6zOEBvVQ>? M3;3bnNCVkeHUh?=
human MLMA cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NID3NGNKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21OU42OSCwTR?= MljJV2FPT0WU
human P30-OHK cell NEDyZ2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3LKUWlvcGmkaYTpc44hd2ZiaIXtZY4hWDNyLV;IT{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVU3NjVibl2= MnP4V2FPT0WU
RPMI-6410 human leukemic lymphoblastoid cell lines NYSxfYZ[S3m2b4TvfIlkyqCjc4PhfS=> NETSO3VEgXSxdH;4bYNqfHliYXfhbY5{fCCUUF3JMVY1OTBiaIXtZY4hdGW3a3XtbYMhdHmvcHjvZoxie3SxaXSgZ4VtdCCuaX7ld{whUUN3ME2wMlA3KM7:TR?= NWTQXnBNPjh{N{W0Oi=>
human HT-29 cells MnTxVJJwdGmoZYLheIlwdiCjc4PhfS=> NHHTZ5VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wOlYh|ryPLh?= NXfnN3BkOjd5OES0PS=>
human NCI-H510A cell M{Po[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV\K[3RyUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUyOEFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14OD6yOkBvVQ>? MmD1V2FPT0WU
human J-RT3-T3-5 cell NWP2VJByT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGouWlR|LWSzMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03QC52MjDuUS=> MkC1V2FPT0WU
human VA-ES-BJ cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnLWTY5pcWKrdHnvckBw\iCqdX3hckBXSS2HUz3CTkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcyNjZ3IH7N NGXBWWpUSU6JRWK=
human T-24 cell NHrkfHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFfsSm1KdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23PE42PiCwTR?= NX\CNpVrW0GQR1XS
human NB69 cell M2HWOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15OT60PEBvVQ>? MVnTRW5ITVJ?
human BALL-1 cells NEPndFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEf0e3MzPCCq M3fhfmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGJCVExvMTDj[YxteyCjZoTldkAzPCCqcoOgZpkhX1OWLUGgZZN{[XluIFfJOVA:OC5yODFOwG0> MXGyNlI3PDF5MB?=
HL60 cells M2j2UnBzd2yrZnXyZZRqd25iYYPzZZk> Ml;JTY4hfmm2cn:gbY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RicILvcIln\XKjdHnvckBw\iCKTE[wJINmdGy|LDDJR|UxRTBwMEig{txO MXGxNlg4PzV7Mx?=
human CTV-1 cell NEnTXWpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnzsTY5pcWKrdHnvckBw\iCqdX3hckBEXFZvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUi0Mlc1KG6P NVrCVoQyW0GQR1XS
human MEL-JUSO cell M4HzNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mli5TY5pcWKrdHnvckBw\iCqdX3hckBOTUxvSmXTU{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg2Njd4IH7N M1f5e3NCVkeHUh?=
human MOLT-4 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTqeVVKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg6NjZ5IH7N NHe5V|ZUSU6JRWK=
human leukemia cell line(CCRF-CEM) NHq2Wm1EgXSxdH;4bYPDqGG|c3H5 NH3JTmZKdiC4aYTyc{BkgXSxdH;4bYNqfHlib3[gZ49ueG:3bnTzJJdmemViZHX0[ZJucW6nZDDvckBKdmirYnn0bY9vKG:oIHj1cYFvKGyndXvlcYliKGOnbHygcIlv\SiFQ2LGMWNGVSluIFnDOVA:OC5yOTFOwG0v M2XURVg6OTd4NEW=
human SW982 cell NVTlNIM2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXPJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OUGuNlMhdk1? NGXBdlJUSU6JRWK=
human NCI-SNU-1 cell NVTKfoR7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX3MR2Q1UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtV25WNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3Ojef-8kEBKSzVyPUm2Mlc4KG6P MYrTRW5ITVJ?
HeLa human cell lines MkHESpVv[3Srb36gZZN{[Xl? Mn60NVQ1KGh? MYDUbIUh[2:vcH;1coQhf2G|IITld5Rm\CCrbjD2bZRzdyCob4KgZY51cXS3bX;yJIFkfGm4aYT5LFUxLSCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToLUBi\2GrboP0JGhmVGFiaIXtZY4h[2WubDDsbY5meyCjZoTldkAyPDRiaIKsJGlFPTB;MD6xJO69VQ>? MVGzOlI2PzF2
human H460 cells NH;SeVZHfW6ldHnvckBie3OjeR?= MnTPNlQhcA>? Mki3RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NEBk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7wrC= NUmxRpZGOjB{MUG1OlQ>
human HCT116 cells NYqxfIduTnWwY4Tpc44h[XO|YYm= MV7BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkGg{txO MXGyNFIyOTV4NB?=
human GP5d cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUG0UXJVUW6qaXLpeIlwdiCxZjDoeY1idiCJUEXkJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAzKG6P NGTYOmJUSU6JRWK=
human SAS cell NHnMWJZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHNCWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyNz61O{BvVQ>? M{iwbHNCVkeHUh?=
human BFTC-905 cell  NHS5O5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWPJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVA5NjNzIH7N NFLqVVlUSU6JRWK=
human LB1047-RCC cell NEnBbpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFrDRlBKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEiuOFIhdk1? MXPTRW5ITVJ?
human BB65-RCC cell NES3PVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFjwU2dKdmirYnn0bY9vKG:oIHj1cYFvKEKENkWtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTFyLkG5JI5O MmWwV2FPT0WU
human KE-37 cell NUHTVZh3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn[xTY5pcWKrdHnvckBw\iCqdX3hckBMTS1|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxNE45PSCwTR?= NYTmPGFVW0GQR1XS
human NCI-H292 cell Moe4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUHFdZFWUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzND6yJI5O NEL3R5lUSU6JRWK=
human HT-1080 cell NWO2UZBiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVv5WoZIUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTF2LkS3JI5O MWLTRW5ITVJ?
human HL60 cells NVPMOXF[S3m2b4TvfIlkyqCjc4PhfS=> MU[0PEBp M4HEZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlEyQCEQvF2= Ml\4NVk{OjF{M{S=
human CAKI-1 cell NF7qd29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFnHTJVIem:5dHigbY5pcWKrdHnvckBw\iCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkAzPCCqcoOgZpkhX1OWLUGgZZN{[XluIFfJOVA:OC5zMjFOwG0> MY[yNlI3PDF5MB?=
human CAKI-1 cell NHL6PFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnTOTY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNlAhdk1? NWrYTFVSW0GQR1XS
human HMV-II cell NEfFendIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGDYUWhKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 MmnhV2FPT0WU
human ES8 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYnHeGlKUW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNlMvQTNibl2= MnP1V2FPT0WU
human NEC8 cell Moj0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHrPTJBKdmirYnn0bY9vKG:oIHj1cYFvKE6HQ{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN|QvOjFibl2= M2rYNHNCVkeHUh?=
human EW-1 cell NXvtdlZsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEnoR5pKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN|gvPjJibl2= NGDMd4tUSU6JRWK=
murine leukemia P388 NWXWOpFoTnWwY4Tpc44h[XO|YYm= MWfBcpRq[2GwY3XyJIFkfGm4aYT5JINienKrZXSgc5V1KGmwII\peJJwKGGpYXnud5QhdXW{aX7lJIxmfWunbXnhJHA{QDhuIFnDOVA:OC5zNDFOwG0> MlPHNVE{PTZzMUC=
human H-EMC-SS cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIK1bnNKdmirYnn0bY9vKG:oIHj1cYFvKEhvRV3DMXNUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTR3LkK4JI5O MXrTRW5ITVJ?
human SNU638 cells M4nL[2N6fG:2b4jpZ:Kh[XO|YYm= NYPB[2Q1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW06XNkO4JINmdGy|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlE2KM7:TR?= MUOyOFk2PjV3Nh?=
human COR-L105 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{jpSWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyxNFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPjBwM{mgcm0> NIe1UJRUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Cytarabine is highly effective against acute leukaemias, which causes the characteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man. [4] Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity. [5]

Protocol

Kinase Assay:[1]
+ Expand

In Vitro Growth Inhibition Assay:

Stock solution of Cytarabine is prepared in absolute ethanol, and serial dilutions of Cytarabine are prepared. CCRF-CEM cells are suspended in RPMI medium supplemented with 10% FBS, 0.1% gentamicin, and 1% sodium pyruvate. The cells are suspended in their respective media to give 10 mL volumes of cell suspension at a final density of 3-6 × 104 cells/mL. Appropriate volumes of Cytarabine solution are transferred to the cell suspensions, and incubation is continued for 72 hours. The cells are spun down and resuspended in fresh Cytarabine -free medium, and final cell counts are determined. The data are analyzed by sigmoidal curve fitting of the cell count versus Cytarabine concentration, and the results are expressed as the IC50 (Cytarabine concentration that inhibits cell growth to 50% of the control value).
Cell Research:[2]
+ Expand
  • Cell lines: Rat leukemic cell lines RCL/0, RO/1 and K7 and human myelomonocytic leukemic U937
  • Concentrations: ~100 μM
  • Incubation Time: 24, 48 and 72 hours
  • Method: Cells are incubated in the presence of different concentrations of Cytarabine at 37 °C for 24, 48, and 72 hours. At the time of 20-, 44-, or 68-hour incubation in the presence of Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4-hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell division times are calculated from eosin counting in parallel with viability assay
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Brown Norway rat with myelocytic leukaemia
  • Formulation: Dissolved in phosphate-buffered saline (pH 7.0) just before use.
  • Dosages: 5 - 1000 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro Water 48 mg/mL (197.35 mM)
DMSO 1 mg/mL (4.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 243.22
Formula

C9H13N3O5

CAS No. 147-94-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756962 Recruiting Acute Myeloid Leukemia Washington University School of Medicine July 6, 2016 Phase 2
NCT01555268 Completed Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia Roswell Park Cancer Institute|National Cancer Institute (NCI)|Amgen October 31, 2011 Phase 1
NCT02203526 Suspended Primary Central Nervious System Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 24, 2014 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT02483000 Not yet recruiting Adult Burkitt Lymphoma|Adult Diffuse Large B-Cell Lymphoma|CD20-Positive Neoplastic Cells Present|Indolent Adult Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory Mature B-Cell Non-Hodgkin Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) March 2017 Phase 1
NCT03019640 Not yet recruiting B-Cell Non-Hodgkin Lymphoma M.D. Anderson Cancer Center March 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Cytarabine | Cytarabine supplier | purchase Cytarabine | Cytarabine cost | Cytarabine manufacturer | order Cytarabine | Cytarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID